ELSALYS BIOTECH has a total of 12 patent applications. It increased the IP activity by 400.0%. Its first patent ever was published in 2016. It filed its patents most often in Canada, China and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and biotechnology are DEBIOVISION INC, ESBATECH - A NOVARTIS COMPANY LLC and DUECKER KLAUS.
# | Country | Total Patents | |
---|---|---|---|
#1 | Canada | 2 | |
#2 | China | 2 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | United States | 2 | |
#5 | WIPO (World Intellectual Property Organization) | 2 | |
#6 | France | 1 | |
#7 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Peptides | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Menguy Thierry | 12 |
#2 | Haegel Helene | 7 |
#3 | Calcei Alexandre | 6 |
#4 | Duong Vanessa | 6 |
#5 | Rozan Caroline | 5 |
#6 | Dufour Florent | 5 |
#7 | Haegel Hélène | 5 |
#8 | Radvanyi Francois | 4 |
#9 | Bernard-Pierrot Isabelle | 4 |
#10 | Bernard Pierrot Isabelle | 1 |
Publication | Filing date | Title |
---|---|---|
FR3061716A1 | NOVEL COMPOUNDS TARGETING CD160 HUMAN | |
KR20170138494A | Anti-TYR03 antibodies and uses thereof |